Cuprous oxide-based nanocrystals with combined chemo/chemodynamic therapy to increase tumor drug sensitivity by reducing mitochondria-derived adenosine-triphosphate. (31st December 2022)

• Record Type: Journal Article
• Authors: He, Haoran; Wu, Jiaming; Liang, Min; Xiao, Yao; Wei, Xuejian; Cao, Yuqin; Chen, Zhiheng; Lin, Tian; Ye, Miaosheng
• Is Part Of: Drug delivery. Volume 29:Number 1(2022)
• Page Start: 3134
• Page End: 3141
• Publication Date: 2022-12-31
• Subjects: Cuprous oxide (Cu2O) -- drug resistance -- P-glycoprotein (P-gp) -- chemodynamic therapy (CDT) -- mitochondria damage; Drug delivery systems -- Periodicals; Drug targeting -- Periodicals; 615.05
• DOI: 10.1080/10717544.2022.2121450
• Languages: English
• ISSNs: 1071-7544

Abstract

Abstract: Gastrointestinal (GI) tumor is a serious disease with high mortality rates and morbidity rates worldwide. Chemotherapy is a key treatment for GI, however, systematic side effects and inevitable drug resistance complicate the situation. In the process of therapy, P-glycoprotein (P-gp) could remove chemotherapy drugs from cells, thus causing multi-drug resistance. Chemodynamic therapy (CDT) utilizing Fenton chemistry has been used for cancer therapy, along with various combination therapies. The reactive oxygen species produced by CDT could inhibit P-gp's efflux pump function, which reduce chemoagents excretion and reverse drug resistance. In the present study, we developed novel nanocrystals (Cu2 O@Pt NCs) to overcome drug resistance by reducing mitochondria-derived ATP through chemo/CDT in GI cancer. Furthermore, in vivo results in tumor-bearing mice demonstrated that treatment with Cu2 O@Pt NCs with CDT and chemotherapy could achieve the most effective antitumor therapeutic effect with the least amounts of adverse effects. As a result, Cu2 O@Pt NCs could provide a promising strategy for chemo/CDT-synergistic therapy.